Notably, the proportion of CD8+ DCs was significantly highest in the combination treatment group (p < 0.001, Figure 6c), clearly indicating that the addition of PD‐1 blockade could markedly promote the enrichment of this critical subset in the tumor. The gene discussed is CD8A; the disease is neoplasm.